Skip to main content
SpringerLink
Log in

Palonosetron—A Single-Dose Antiemetic Adjunct for Hepatic Artery Radioembolization: A Feasibility Study

  • Clinical Investigation
  • Published:
CardioVascular and Interventional Radiology Aims and scope Submit manuscript

Abstract

Nausea and vomiting may occur in a significant minority of patients following hepatic artery embolization with yttrium-90 spheres (K. T. Sato et al. Radiology 247:507–515, 2008). This encumbers human and economic resources and undercuts the assertion that it is as a well-tolerated outpatient treatment. A single intravenous dose of palonosetron HCl was administered before hepatic artery embolization with yttrium-90 spheres to ameliorate posttreatment nausea and vomiting, in 23 consecutive patients. The patients were discharged the day of procedure on oral antiemetics, steroids, and blockers of gastric acid release. All patients had clinical and laboratory evaluation at 2 weeks after the procedure. The data were gathered and reviewed retrospectively. At 2-week follow-up, none reported significant nausea, vomiting, additional antiemetic use, need for parenteral therapy, hospital readmission, or palonosetron-related side effects. All patients recovered from postembolization symptoms within a week after treatment. In conclusion, this retrospective study suggests that single-dose palonosetron is feasible, safe, and effective for acute and delayed nausea and vomiting in this group of patients. The added cost may be offset by benefits.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. El-Serag HB, Davila JA, Petersen NJ et al (2003) The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139(10):817–823

    PubMed  Google Scholar 

  2. Kennedy AS, Coldwell D, Nutting C et al (2006) Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412–425

    PubMed  CAS  Google Scholar 

  3. Aapro MS, Grunberg SM, Manikhas GM et al (2006) A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol 17(9):1441–1449

    Article  PubMed  CAS  Google Scholar 

  4. Gralla R, Lichinitser M, Van Der Vegt S et al (2003) Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 14(10):1570–1577

    Article  PubMed  CAS  Google Scholar 

  5. Murthy R, Nunez R, Szklaruk J et al (2005) Yttrium–90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 5(Suppl 1):S41–S55

    Article  Google Scholar 

  6. Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23

    PubMed  Google Scholar 

  7. Sato KT, Lewandowski RJ, Mulcahy MF et al (2008) Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology 247(2):507–515

    Article  PubMed  Google Scholar 

  8. de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76(8):1055–1061

    PubMed  Google Scholar 

  9. Tarricone R, Girolami F (2005) Economic evaluation of a new antiemetic drug—palonosetron versus ondansetron: assessment of the drug price ratio in five European countries. Clin Drug Invest 25(9):597–608

    Article  Google Scholar 

  10. Geling O, Eichler HG (2005) Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol 23(6):1289–1294

    Article  PubMed  CAS  Google Scholar 

  11. Navari RM (2006) Palonosetron: a second-generation 5-hydroxytryptamine receptor antagonist. Future Oncol 2(5):591–602

    Article  PubMed  CAS  Google Scholar 

  12. Eisenberg P, Figueroa-Vadillo J, Zamora R et al (2003) Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 98(11):2473–2482

    Article  PubMed  CAS  Google Scholar 

  13. MASCC guidelines. Available at: http://www.mascc.org/media/Resource_centers/MASCC_Guidelines_Update.pdf

  14. NCCN guidelines. Available at: http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf

Download references

Author information

Authors and Affiliations

  1. Mallinckrodt Institute of Radiology, Washington University Medical Center, 510 South Kingshighway, St. Louis, MO, 63110, USA

    Nasir H. Siddiqi

  2. Department of Radiation Oncology, Robert Wood Johnson Medical School, New Brunswick, NJ, 08901, USA

    Atif J. Khan

  3. Dana Farber/Brigham and Women’s Cancer Center/Harvard Medical School, Boston, MA, 02115, USA

    Phillip M. Devlin

Authors
  1. Nasir H. Siddiqi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Atif J. Khan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phillip M. Devlin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nasir H. Siddiqi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siddiqi, N.H., Khan, A.J. & Devlin, P.M. Palonosetron—A Single-Dose Antiemetic Adjunct for Hepatic Artery Radioembolization: A Feasibility Study. Cardiovasc Intervent Radiol 32, 47–51 (2009). https://doi.org/10.1007/s00270-008-9428-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00270-008-9428-z

Keywords

Search

Navigation